Biostage (BSTG) – Press Releases
-
Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency
-
Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results
-
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
-
Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)
-
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
-
Biostage to Host Investor Call
-
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
-
Biostage Appoints Ron Packard to Board of Directors
-
Biostage Announces $6 Million Financing to Advance Clinical Trial
-
Biostage Announces Chairman and CEO Transition
-
Biostage Amends CEO Employment Agreement
-
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
-
New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant
-
Biostage Reports Corporate Highlights and Third Quarter Financial Results
-
Biostage Schedules Conference Call and Webcast for Q3 2022 Results
-
Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair
-
Biostage Announces Appointment of New Chief Financial Officer
-
Biostage Reports Corporate Highlights and Second Quarter Financial Results
-
Biostage Schedules Conference Call and Webcast for Q2 2022 Results
-
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
-
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
-
Biostage Announces $5.1 Million Financing to Advance Clinical Trial
-
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
-
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
-
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
-
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
-
Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar
-
Biostage Announces Court's Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense
-
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets
-
Biostage Hires David Green as Chief Executive Officer
-
Biostage Reports Q3 2021 Financial Results
-
Biostage™ Appoints Jerry He to Board of Directors and Completes Private Placement of $2.6 Million to Continue Its Clinical Transition
-
Biostage Reports Q2 2021 Financial Results
-
Biostage Reports Q1 2021 Financial Results
-
Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance
-
Biostage Strengthens Board of Directors with Appointment of Herman Sanchez
-
Biostage Reports Third Quarter 2020 Financial Results
-
Biostage Reports Second Quarter 2020 Financial Results
-
Biostage Reports First Quarter 2020 Financial Results
-
Biostage Reports 2019 Financial Results
-
Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant
-
Biostage Submitted Official Response to FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
-
Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
-
Biostage Receives Response from the FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
-
Biostage Reports Third Quarter 2019 Financial Results
-
Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update
-
Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan™ Esophageal Implant for Treatment of Esophageal Conditions
-
Biostage Reports Second Quarter 2019 Financial Results
-
Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update
-
Biostage Reports First Quarter 2019 Financial Results
Back to BSTG Stock Lookup
